A large-scale genetic study has provided strong evidence that the development of insulin resistance – a risk factor for type 2 diabetes and heart attacks and one of the key adverse consequences of obesity – results from the failure to safely store excess fat in the body.
An approach that could reduce the chances of drugs failing during the later stages of clinical trials has been demonstrated by a collaboration between the University of Cambridge and pharmaceutical company GlaxoSmithKline (GSK).
A new genetic study of over 200,000 women reveals the underlying mechanisms of polycystic ovary syndrome, as well as potential interventions.
Graham Ladds, lecturer in pharmacology, discusses the controversy around a group of drugs used to treat Type 2 diabetes.
Scientists have found that some drugs from a group of anti-diabetic treatments may, in certain circumstances, act on glucagon receptors in the body, meaning that they could also potentially enable the release of sugar into the bloodstream.
Sugar sweetened drinks may give rise to nearly two million diabetes cases over ten years in the US and 80,000 in the UK, estimates a study published in the BMJ.
Screening to identify type 2 diabetes followed by early treatment could result in substantial health benefits, according to new research published today in Diabetes Care that combined large scale clinical observations and innovative computer modelling.
Drinking water or unsweetened tea or coffee in place of one sugary drink per day can reduce the risk of type 2 diabetes, according to research published today in the journal Diabetologia.